Toggle Summary March 13, 2015
Minerva Neurosciences Announces $31 Million Financing
View HTML
Toggle Summary January 21, 2015
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
View HTML
Toggle Summary January 20, 2015
Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
Funding supports Minerva continuing to advance the clinical program for MIN-101, the company's investigational compound in development for treatment of schizophrenia
View HTML
Toggle Summary January 5, 2015
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates
View HTML
Toggle Summary December 3, 2014
Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
New Formulation to be Used in Planned Phase 2b Clinical Trial Has Been Developed to Offer Improved Safety, Tolerability and Pharmacokinetic Profile
View HTML
Toggle Summary November 25, 2014
Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO
View HTML
Toggle Summary November 13, 2014
Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit
View HTML
Toggle Summary November 6, 2014
Minerva Neurosciences Reports Third Quarter 2014 Financial Results
View HTML
Toggle Summary October 30, 2014
Minerva Neurosciences to Host Third Quarter 2014 Financial Results Webcast and Conference Call
View HTML
Toggle Summary September 22, 2014
Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
Bioavailability Study in U.S. for Investigational Therapy in Development for Treatment of Insomnia to be Initiated
View HTML
